Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idelalisib +/- Rituximab in Elderly Untreated CLL/SLL
NCT01203930Phase 2Terminated
- Sponsor
- Gilead Sciences
- Start
- Oct 2010
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of idelalisib in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (2 arms), sponsored by Gilead Sciences. Primary endpoint: Overall Response Rate up to 28 Months. Started Oct 2010; status: terminated.
02
Drugs
idelalisib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT01203930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01203930.